Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

European urology oncology·2026
Same author

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

ESMO real world data and digital oncology·2026
Same author

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.

The French journal of urology·2023
Same author

Retropubic tape surgery for stress urinary incontinence: can women be cured without voiding dysfunction?

World journal of urology·2023
Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

[Bone prevention in prostate cancer].

T Bessede1, N Houede, T Lebret

  • 1Service d'Urologie, Hôpital Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin- Bicêtre Cedex, France. thomas.bessede@gmail.com

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|March 15, 2011
PubMed
Summary
This summary is machine-generated.

Hormonal deprivation in prostate cancer patients increases bone loss and fracture risk. Treatments like bisphosphonates and RANK-inhibitors can prevent bone metastasis events.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 3, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

Area of Science:

  • Oncology
  • Endocrinology
  • Bone Metabolism

Context:

  • Prostate cancer treatment often involves hormonal deprivation, leading to significant bone density loss.
  • Increased fracture risk is a major concern for patients undergoing androgen deprivation therapy.
  • Bone demineralization is a quantifiable consequence of hormonal changes.

Purpose:

  • To summarize the impact of hormonal deprivation on bone health in prostate cancer patients.
  • To review current and potential therapeutic strategies for mitigating bone loss and fracture risk.
  • To discuss the role of bone-targeting agents in preventing skeletal-related events.

Summary:

  • Hormonal deprivation therapy for prostate cancer exacerbates bone loss and elevates fracture risk.
  • Bone Mineral Density (BMD) quantifies demineralization, which can be managed through lifestyle, diet, or novel therapeutic agents.
  • Intravenous bisphosphonates and subcutaneous RANK-inhibitors are effective in preventing bone metastasis-related complications.

Impact:

  • Highlights the critical need for bone health management in prostate cancer patients.
  • Identifies therapeutic avenues for preserving bone integrity and reducing skeletal morbidity.
  • Suggests potential benefits of bone-modulating agents in managing metastatic disease progression.